{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:07:41Z","timestamp":1789110461762,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013105","name":"Shanghai Rising-Star Program","doi-asserted-by":"publisher","award":["23QC1400600"],"award-info":[{"award-number":["23QC1400600"]}],"id":[{"id":"10.13039\/501100013105","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004921","name":"Shanghai Jiao Tong University","doi-asserted-by":"publisher","award":["YG2023QNA09"],"award-info":[{"award-number":["YG2023QNA09"]}],"id":[{"id":"10.13039\/501100004921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018555","name":"Science and Technology Program of Guizhou Province","doi-asserted-by":"publisher","award":["Qiankeherencai XKBF [2025]025"],"award-info":[{"award-number":["Qiankeherencai XKBF [2025]025"]}],"id":[{"id":"10.13039\/501100018555","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404929"],"award-info":[{"award-number":["82404929"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82400135"],"award-info":[{"award-number":["82400135"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32471528"],"award-info":[{"award-number":["32471528"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218700","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T06:58:05Z","timestamp":1782802685000},"page":"218700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Differential bioenergetic reprogramming driven by sorafenib reveals therapeutic vulnerabilities in biliary tract cancers"],"prefix":"10.1016","volume":"659","author":[{"given":"Wenhua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beixuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuying","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziru","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7572-1748","authenticated-orcid":false,"given":"Ziming","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6110-0185","authenticated-orcid":false,"given":"Yingbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10272","key":"10.1016\/j.canlet.2026.218700_bib1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.canlet.2026.218700_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41575-025-01153-w","article-title":"Cholangiocarcinoma 2026: status quo, unmet needs and priorities","volume":"23","author":"Banales","year":"2026","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.canlet.2026.218700_bib3","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/gutjnl-2018-316039","article-title":"Genomic ERBB2\/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis","volume":"68","author":"Li","year":"2019","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.canlet.2026.218700_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103706","article-title":"Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets","volume":"9","author":"Kehmann","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.canlet.2026.218700_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217540","article-title":"Current status and prospects of targeted therapy for cholangiocarcinoma based on molecular characteristics","volume":"614","author":"Cui","year":"2025","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.canlet.2026.218700_bib6","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/ijms18020418","article-title":"Targeting angiogenesis in biliary tract cancers: an open option","volume":"18","author":"Simone","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.canlet.2026.218700_bib7","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol. Cancer Therapeut."},{"issue":"19","key":"10.1016\/j.canlet.2026.218700_bib8","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.canlet.2026.218700_bib9","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.canlet.2026.218700_bib10","first-page":"1106","article-title":"Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: real-life data on liver disease, treatment and prognosis","volume":"11","author":"Adhoute","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"5","key":"10.1016\/j.canlet.2026.218700_bib11","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2021.01.035","article-title":"Combined hepatocellular-cholangiocarcinoma: an update","volume":"74","author":"Beaufr\u00e8re","year":"2021","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218700_bib12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.bjc.6605458","article-title":"Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial","volume":"102","author":"Bengala","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2026.218700_bib13","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1007\/s10637-011-9719-0","article-title":"SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma","volume":"30","author":"El-Khoueiry","year":"2012","journal-title":"Invest. N. Drugs"},{"issue":"18","key":"10.1016\/j.canlet.2026.218700_bib14","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1016\/j.ejca.2014.09.013","article-title":"Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme","volume":"50","author":"Moehler","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218700_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.101993","article-title":"Evolving role of regorafenib for the treatment of advanced cancers","volume":"86","author":"Grothey","year":"2020","journal-title":"Cancer Treat Rev."},{"issue":"4","key":"10.1016\/j.canlet.2026.218700_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000776","article-title":"Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503)","volume":"5","author":"Iwasa","year":"2020","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.canlet.2026.218700_bib17","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218700_bib18","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.bbrc.2020.10.083","article-title":"Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis","volume":"534","author":"Li","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"16","key":"10.1016\/j.canlet.2026.218700_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20164048","article-title":"Sorafenib-induced apoptosis in hepatocellular carcinoma is reversed by SIRT1","volume":"20","author":"Garten","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.canlet.2026.218700_bib20","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial","volume":"57","author":"Bruix","year":"2012","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.canlet.2026.218700_bib21","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.21037\/jgo-2025-83","article-title":"Recent advancements in systemic therapy for biliary tract cancers: a literature review","volume":"16","author":"Hussain","year":"2025","journal-title":"J. Gastrointest. Oncol."},{"issue":"15","key":"10.1016\/j.canlet.2026.218700_bib22","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1002\/cncr.32964","article-title":"A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer","volume":"126","author":"Kim","year":"2020","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.canlet.2026.218700_bib23","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1158\/1078-0432.CCR-16-0919","article-title":"Sorafenib in patients with hepatocellular carcinoma\u2014results of the observational INSIGHT study","volume":"23","author":"Ganten","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"24","key":"10.1016\/j.canlet.2026.218700_bib24","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","article-title":"Sorafenib for the treatment of advanced renal cell carcinoma","volume":"12","author":"Kane","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.canlet.2026.218700_bib25","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s10637-009-9321-x","article-title":"Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer","volume":"28","author":"Okamoto","year":"2010","journal-title":"Invest. N. Drugs"},{"issue":"5","key":"10.1016\/j.canlet.2026.218700_bib26","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","article-title":"Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors","volume":"23","author":"Strumberg","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.canlet.2026.218700_bib27","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/j.1349-7006.2008.00837.x","article-title":"Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors","volume":"99","author":"Minami","year":"2008","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.canlet.2026.218700_bib28","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.cmet.2020.04.011","article-title":"Low-dose sorafenib acts as a mitochondrial uncoupler and ameliorates nonalcoholic steatohepatitis","volume":"31","author":"Jian","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.canlet.2026.218700_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113902","article-title":"Dose-dependent regulation of mitochondrial function and cell death pathway by sorafenib in liver cancer cells","volume":"176","author":"Rodr\u00edguez-Hern\u00e1ndez","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218700_bib30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41467-017-02391-6","article-title":"Perturbation-response genes reveal signaling footprints in cancer gene expression","volume":"9","author":"Schubert","year":"2018","journal-title":"Nat. Commun."},{"issue":"20","key":"10.1016\/j.canlet.2026.218700_bib31","doi-asserted-by":"crossref","first-page":"10934","DOI":"10.1093\/nar\/gkad841","article-title":"Expanding the coverage of regulons from high-confidence prior knowledge for accurate estimation of transcription factor activities","volume":"51","author":"M\u00fcller-Dott","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218700_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/bioadv\/vbac016","article-title":"decoupleR: ensemble of computational methods to infer biological activities from omics data","volume":"2","author":"Badia-i-Mompel","year":"2022","journal-title":"Bioinform. Adv."},{"issue":"15","key":"10.1016\/j.canlet.2026.218700_bib33","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","article-title":"SynergyFinder: a web application for analyzing drug combination dose-response matrix data","volume":"33","author":"Ianevski","year":"2017","journal-title":"Bioinformatics"},{"issue":"3","key":"10.1016\/j.canlet.2026.218700_bib34","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2022.04.038","article-title":"Metabolic reprogramming in cholangiocarcinoma","volume":"77","author":"Raggi","year":"2022","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218700_bib35","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-025-02282-z","article-title":"D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma","volume":"10","author":"Pedretti","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218700_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217714","article-title":"Metabolic reprogramming in cholangiocarcinoma cancer stem cells: emerging therapeutic paradigms","volume":"622","author":"Wang","year":"2025","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.canlet.2026.218700_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/pcmedi\/pbaf021","article-title":"Molecular mechanisms and genetic features of cholangiocarcinoma: implications for targeted therapeutic strategies","volume":"8","author":"Lu","year":"2025","journal-title":"Precis. Clin. Med."},{"issue":"9","key":"10.1016\/j.canlet.2026.218700_bib38","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1158\/2159-8290.CD-24-1383","article-title":"Generation of a biliary tract cancer cell line atlas identifies molecular subtypes and therapeutic targets","volume":"15","author":"Vijay","year":"2025","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.canlet.2026.218700_bib39","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev-biodatasci-101424-120950","article-title":"Network-based approaches for drug target identification","volume":"8","author":"Koutsandreas","year":"2025","journal-title":"Annu. Rev. Biomed. Data Sci."},{"issue":"1","key":"10.1016\/j.canlet.2026.218700_bib40","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1038\/s41467-023-40022-5","article-title":"Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers","volume":"14","author":"El-Botty","year":"2023","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.canlet.2026.218700_bib41","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41416-023-02394-9","article-title":"Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities","volume":"129","author":"Machado","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2026.218700_bib42","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","article-title":"Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials","volume":"29","author":"Yap","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218700_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218208","article-title":"Loss of branched-chain amino acid (BCAA) metabolism mediated by IGF2BP1-LPAL2-YBX1 interaction promotes malignancy in gallbladder cancer","volume":"639","author":"Li","year":"2026","journal-title":"Cancer Lett."},{"issue":"14","key":"10.1016\/j.canlet.2026.218700_bib44","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1128\/MCB.25.14.6225-6234.2005","article-title":"Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis","volume":"25","author":"Li","year":"2005","journal-title":"Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.canlet.2026.218700_bib45","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a014225","article-title":"MYC and mitochondrial biogenesis","volume":"4","author":"Morrish","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"7170","key":"10.1016\/j.canlet.2026.218700_bib46","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nature06322","article-title":"mTOR controls mitochondrial oxidative function through a YY1\u2013PGC-1\u03b1 transcriptional complex","volume":"450","author":"Cunningham","year":"2007","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.canlet.2026.218700_bib47","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/nm.4438","article-title":"Human primary liver cancer\u2013derived organoid cultures for disease modeling and drug screening","volume":"23","author":"Broutier","year":"2017","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.canlet.2026.218700_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.03.088","article-title":"Establishment of patient-derived organoids and drug screening for biliary tract carcinoma","volume":"27","author":"Saito","year":"2019","journal-title":"Cell Rep."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T06:36:45Z","timestamp":1789108605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526004647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":48,"alternative-id":["S0304383526004647"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218700","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential bioenergetic reprogramming driven by sorafenib reveals therapeutic vulnerabilities in biliary tract cancers","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218700","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218700"}}